GlassScriptPhysician profile
Kettlie Daniels
NPI 1790775054
$4,808.96
in general payments reported to CMS, 2019-2025
24 companies · $908 in 2025
The $908 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $709 · 2021: $688 · 2022: $315 · 2023: $827 · 2024: $409 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.05 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,082.79 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $450.61 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $423.63 | 2019-2025 | Ingrezza |
| Allergan, INC. | $393.46 | 2019-2020 | |
| Axsome Therapeutics, INC. | $361.51 | 2023-2025 | Auvelity |
| Alkermes, INC. | $347.40 | 2023-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.92 | 2022-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $213.59 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $175.81 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $156.91 | 2020-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $140.67 | 2020-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $138.26 | 2020-2025 | Rexulti |
| Braeburn INC. | $113.15 | 2025 | Brixadi |
| Abbvie INC. | $92.50 | 2021-2024 | |
| Noven Pharmaceuticals, INC. | $81.49 | 2023 | Xelstrym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $78.90 | 2023 | Igalmi |
| Corium, LLC | $60.03 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $43.57 | 2020-2022 | |
| Shire North American Group INC | $32.39 | 2019 | |
| Alfasigma USA, INC. | $23.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.71 | 2022 | |
| Merck Sharp & Dohme LLC | $16.47 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.80 | 2021 | |
| Noven Therapeutics, LLC | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kettlie Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.